The effect of tranexamic acid in reducing mortality and the need for blood transfusion in trauma patients with significant bleeding

Phase 2

• Conditions: Condition 1: Tranexamic acid. Condition 2: transfusion.; Anticoagulant antagonists, vitamin K and other coagulants; Blood transfusion (without reported diagnosis)

• Registration Number: IRCT2016040816473N6
• Lead Sponsor: Vice chancellor for research, Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

age>5 years; Systolic blood pressure<90 mmHg; Heart rate>110; no indication for surgery

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortallity. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.;Need for blood transfusion. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.

Secondary Outcome Measures

Name	Time	Method
Hospitalization days in ICU. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.;Organ Failure. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.;Thrombotic complications. Timepoint: From admission until discharge or death, and a maximum of one month after hospitalization. Method of measurement: via clinical records.